Julia Riley, MD
Dermatology · Chicago, ILNPI 1982051165
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $7,570 of the $8,989 with a category attached, or 84.2%. Novartis accounts for 80.1% of it on its own, with 6 other manufacturers making up the rest. 2025 is the largest year on record at $3,279, 3.7 times the $879 reported in 2019.
Across 34 payments — averaging $264.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$7K
- AbbVie$1K
- Chugai Pharmaceutical Co., Ltd.$450
- UCB, Inc.$60
- Pfizer$43
- Lilly USA, LLC$19
- plus $19 from 1 others
Across 31 payments — averaging $2684.05 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Incyte Corporation$60K
- Novartis$23K
What the payments were for
- Consulting fees$7,57084%
- Food & beverage$1,40416%
- Education$150%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 14 | $7,202 |
| AbbVie(2 entities) | 13 | $1,196 |
| Chugai Pharmaceutical Co., Ltd. | 1 | $450 |
| UCB, Inc. | 2 | $60 |
| Pfizer | 2 | $43 |
| Lilly USA, LLC | 1 | $19 |
| Incyte Corporation | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- COSENTYX$2,044
- Non-Covered Product$450
- Skyrizi$400
- Humira$234
How this compares
$8,989 in reported general payments places this provider in the 75th percentile of 606 dermatology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 65 | $234,833 |
| Dupixent SyringeDupilumab | 17 | $66,529 |
| Clobetasol Propionate | 66 | $3,205 |
| Fluocinonide | 32 | $1,335 |
| Doxycycline Monohydrate | 25 | $1,204 |
| Ketoconazole | 81 | $1,154 |
| Azelaic Acid | 12 | $1,095 |
| Clindamycin Phosphate | 41 | $1,079 |
| Triamcinolone Acetonide | 96 | $974 |
| Tretinoin | 14 | $959 |
| Betamethasone Dipropionate | 13 | $812 |
| ValacyclovirValacyclovir Hcl | 28 | $777 |
| Ciclopirox | 21 | $603 |
| Metronidazole | 13 | $581 |
| Minoxidil | 47 | $544 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Chicago
- Raj ChovatiyaChicago$3.6M
- Peter LioChicago$2.4M
- Elizabeth KiracofeChicago$1.6M
- Carolyn JacobChicago$566K
- Walter LiszewskiChicago$414K
- Omer IbrahimChicago$313K
- Caroline RobinsonChicago$308K
- Smita AggarwalChicago$214K
- Tracee BlackburnChicago$180K
- Faiyaaz KalimullahChicago$137K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.